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Christakis Damianou1,2*, Christos Christofi1 and Nicos Mylonas3Abstract
Background: The aim of the proposed study was to conduct a feasibility study using a flat rectangular (3 × 10 mm2)
transducer operating at 5 MHz for removing atherosclerotic plaque in an in vivo model. The proposed method can be
used in the future for treating atherosclerotic plaques in humans.
Methods and results: The plaque in the rabbits was created using high cholesterol diet for 4 months. The amount of
plaque removed was studied as a function of intensity, with a fixed pulse repetition frequency (PRF), and duty factor (DF).
Conclusions: The amount of plaque removed is directly related to the acoustic intensity. It was found that the presence
of bubbles accelerates the removal of plaque. In order to ensure that pure mechanical mode ultrasound was used, the
intensity used does not produce temperatures that exceed 1°C.
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Atherosclerosis is a condition in which fatty material
collects along the walls of arteries. This fatty material
thickens and may eventually block the arteries [1]. The
plaque is composed of distinctly morphological features
including a fibrous cap comprised of smooth muscle
cells, fibrotic tissue, and lipid core containing fat-laden
macrophages and extracellular lipids [1]. In the advanced
stage, atherosclerotic plaque contains large amounts of
calcium salt [2], which significantly increases the mech-
anical properties of the plaque. Histology studies have
also led to the recognition that plaque structure influ-
ences the risk of plaque rupture. Specifically, a plaque
with a thin fibrous cap and a large lipid core is more
prone to rupture [3].
Lifestyle changes, such as eating a healthy diet and exer-
cising, are often the best treatment for atherosclerosis. But
sometimes, medication or surgical procedures may be rec-
ommended as well [4]. Atherosclerosis treatment may
require special surgical procedures such as Balloon Angio-
plasty [5-7], balloon angioplasty and stenting [8,9], cut-
ting balloon [10-12], atherectomy [13,14], and surgical* Correspondence: cdamianou@cytanet.com.cy
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unless otherwise stated.bypass [15,16], to open an artery and improve blood
flow. The main treatment for the carotid artery is end-
arterectomy [17-19].
Recently therapeutic ultrasound has been employed in
the hospitals for many applications. Therapeutic ultra-
sound was utilized on prostate carcinoma in rats, where
it was proven that thermal ultrasound has the potential
to treat small localized prostate cancer lesions [20]. Clin-
ical trials utilizing thermal ultrasound and ultrasound
imaging were published thereafter [21,22]. The two
dominant clinically available systems using transrectal
HIFU are Ablatherm HIFU (Technomed International,
Lyon, France) and HIFU Sonablate 500 (Focal Surgery,
Milpitas, CA now SonaCare Medical, Charlotte, NC,
USA). Recent advances of the transrectal device includes
a phased-array probe for more efficient treatment of the
prostate [23]. Another clinical success that employs
therapeutic ultrasound with magnetic imaging guidance
(MRI) is the technology introduced by the Israeli com-
pany InSightec [24]. This technology resulted in the first
commercial system for the treatment of uterine fibroids
(using also thermal ultrasound), which received approval
by the Food and Drug Administration (FDA) in 2004.
This system is incorporated in the table of a General
Electric MRI scanner. The system initially was approved
for the treatment of various gynecological tumors [25-28].
An endorectal thermal ultrasound system produced by thetral. This is an Open Access article distributed under the terms of the Creative
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of prostate cancer [29,30]. The same company utilized
thermal ultrasound for pain palliation of bone metastases
[31-33]. Finally, InSightec developed a transcranial MRI-
guided HIFU system for the non-invasive treatment of
various brain diseases [34] such as brain cancer, and
Parkinson’s disease (thermal ultrasound), and stroke (mech-
anical ultrasound using microbubbles). Philips Healthcare,
Netherland showed interest in this technology recently and,
as a result the MRI guide HIFU system, Sonalleve was
developed as a commercial product [35] for the treat-
ment of uterine fibroids and bone palliation using ther-
mal ultrasound. This system is incorporated in the table
of a Philips MRI scanner. Besides the two systems pro-
viding therapy for prostate diseases, there is another
technology from China [36-39] that establishes extra-
corporeal thermal ablation for various organ using fo-
cused ultrasound and ultrasonic imaging (liver, breast,
kidney, osteosarcoma, and pancreas).
Recently at the University of Minnesota, researchers
attempted to treat atherosclerosis with noninvasive method
such as HIFU [40]. The University of Minnesota recently
developed a new HIFU technology that performs noninva-
sive, real-time ultrasonic imaging and localized treatment
using thermal ultrasound.
In this paper, pulsed ultrasound was utilized for the
first time for removing atherosclerotic plaque in an
in vivo rabbit model. In order to ensure that pure mech-
anical mode ultrasound was used, the protocols were de-
signed so that the temperature does not exceed 1°C.
However, to our knowledge, no prior studies have been re-
ported on ultrasound ablation of atherosclerotic plaque
using pulsed ultrasound.
This paper describes a feasibility study that was carried
out, in order to investigate the effectiveness of a thera-
peutic protocol in removing atherosclerotic plaque through
pulsed ultrasound using a planar unfocused transducer op-
erating at 5.3 MHz. An existing good model for developing
atherosclerotic plaque [41,42] was used. In this animal
model, high cholesterol diet is administered to rabbits.
As a result, atherosclerotic plaque is formed in various
arteries of the rabbit (aorta, abdominal, and carotid).
The efficacy of pulsed ultrasound was monitored with
ultrasonic imaging. The growth of the plaque was evalu-
ated with histology of the arteries. Although the aorta is
the biggest artery with size comparable to important ar-
teries of humans (for example coronary), we have
chosen to use the carotid artery for therapy, mainly to
avoid breathing and because access to this artery with
ultrasound is easy.
The main ultrasonic parameter evaluated for its effect
on the treatment was the intensity. The duty factor (DF)
was varied in just one experiment to show that there is
limit on the value of DF to be used, since high DF maycause thermal effects. Thus, the main therapy parameter
used in this study was the acoustic intensity.
Materials and methods
Experimental setup
Figure 1A shows the schematic diagram of the ultrasound
system. The apparatus is divided into two subsystems: (1)
ultrasound generation, and (2) passive cavitation detection
(a hydrophone was employed to monitor cavitation activ-
ity). A 5.3-MHz sinusoidal input was generated by a func-
tion generator (Agilent 33120 15 MHz Function/Arbitrary
Waveform Generator, Englewood, CO, USA). The elec-
trical signal is amplified by an RF amplifier (75 W, AR,
Souderton, PA, USA), and then delivered through an im-
pedance matching network designed exclusively for this
particular transducer. Figure 1B shows the coupling of the
transducer to the rabbit carotid artery.
The active size of the transducer is 3 × 10 mm2. The
transducer material is P762-type PZT piezoceramic
(Quartz & Silice, Nemours, France) with air backing, op-
erating at 5.3 MHz. Figure 2A shows the transducer
holder manufactured using acrylonitrile butadiene styr-
ene (ABS). The ABS parts of the robot were designed
using computer-aided design (CAD) software (Microsta-
tion V8, Bentley Systems, Inc., Exton, PA, USA). The
files were then exported to computer-aided manufactur-
ing (CAM) software (Insight V. 6.4.1, Stratasys Inc.,
Eden Prairie, Minnesota, USA). The files were sent to a
3D printer (FDM400, Stratasys, 7665 Commerce Way,
Eden Prairie, MN, USA) for production. This structure
contains two inlets for transducer cooling and two inlets
for transducer wiring. Figure 2B shows the drawing of
the transducer holder indicating the water inlets and
wiring inlets. Figure 2C shows the final assembly of the
transducer inside the plastic holder. Because in future
clinical trials the transducer will be incorporated in a
catheter that will be guided through arteries (1–3 mm
wide), the transducer element must be as compact as
possible. Since the catheter will be inserted in the body,
after the treatment the catheter will be destroyed (there-
fore it is considered consumable).
Using the acoustic balance technique [43], the electro-
acoustic efficiency of the applicator was measured (55%
at 5.3 MHz). The external face of the transducer was
cooled by a continuous flow of degassed water circulat-
ing the length of the transducer. The water cooling cir-
cuit was maintained at 15°C and was driven by a
Masterflex peristaltic pump (Cole Parmer Instrument
Co., Chicago, IL, USA) at a flow of 0.15 L/min.
Sonication parameters
The spatial-average pulse-average (SAPA) intensity was
estimated, by dividing the power with the surface area of


















Figure 1 System diagram and coupling to animal. Diagram of the pulsed high intensity ultrasound system which includes a generator/amplifier,
a temperature reader, and a passive cavitation detector; (A) and coupling of the transducer to the carotid artery (B).
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was 5 min because the ultrasound bubbles injected in
the circulation system of the rabbit last for 5 min. Sev-
eral 5-min sessions were used to effectively remove all
the plaque desired.
Cavitation detection
The cavitation activity was monitored using a hydro-
phone (Specialty Eng. Associates, Irvine, CA, USA). The
signal from the hydrophone was fed to a custom-made
amplifier (×20 amplification), and was high-pass-filtered
using a custom-made filter. Fast Fourier transform (FFT)spectrums of the acoustic emission signals were acquired
using a PC-based interface card (Gage, Lockport, NY,
USA). The hydrophone was aligned perpendicular to the
sample under investigation.
Animals and diet
Totally 17 New Zealand rabbits (3.8–4 kg) were used
during the experiments. The rabbits were divided ran-
domly into two groups. The animals of group A (n = 2)
were fed with normal chow. In group B (n = 15) the ani-
mals were fed with 2% high cholesterol diet (T2030,
Harlan laboratories SRL, Udine, Italy). Twelve (12)
AB
C
Figure 2 Transducer design. Transducer holder manufactured
using ABS. This structure contains two inlets for transducer cooler
and two inlets for the transducer wires (A). Drawing of the
transducer holder indicating the water inlets and wiring inlets
(B). Final assembly of the transducer inside the plastic holder (C).
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treatment. These rabbits were used as a reference
for evaluating the reduction of artery at the first month
(n = 3), second month (n = 3), third month (n = 3), and
fourth month (n = 3). Three (n = 3) rabbits were treated
with ultrasound and microbubbles. Animals going
through the high cholesterol diet were sacrificed to a
maximum of 4 months, because severe side effects ap-
peared (hypercholesteremic side effects such as weight
loss, appetite loss, and jaundice).In vivo experiments
The rabbits were anaesthetized using a mixture of
500 mg of ketamine (100 mg/mL, Aveco, Ford Dodge,
IA, USA), 160 mg of xylazine (20 mg/mL, Loyd Laborator-
ies, Shenandoah, IA, USA), and 20 mg of acepromazine
(10 mg/mL, Aveco, Ford Dodge, IA) at a dose of 1 mL/kg.
The animal experiments protocol was approved by the
national body in Cyprus responsible for animal studies
(Ministry of Agriculture, Animal Services).
Statistical analysis
Statistical analysis was performed using the software
SIMA. Paired t-test analyses were used to compare
lumen area reduction with and without high cholesterol.
Correlation analyses were performed using linear regres-
sion analysis with 95% confidence intervals (p = 0.05).
Same analysis was performed when assessing the effect
of ultrasonic intensity on the plaque reduction.
Ultrasound bubbles
Prior to the application of ultrasound a bolus of an
ultrasound contrast agent (SonoVue; Bracco SpA, Milan,
Italy) was injected intravenously through the ear vein at
a dose of 0.02 mL/kg.
Hematoxylin and eosin (ΗΕ) staining
By the end of the experiments the rabbits were sacrificed
and transcardially perfused with 60 mL phosphate-
buffered saline and 120 mL 4% paraformaldehyde. The
artery was then soaked in paraformaldehyde for 24 h.
Hematoxylin and eosin staining was performed on
paraffin-embedded artery with a slice thickness of 10 μm
for histologic examinations.
Ultrasonic imaging
An ultrasonic system (Philips HD7 series Ultrasound
Systems, Philips and Neusoft Medical Systems Co. Ltd,
Shenyang, China) was used to monitor the plaque re-
moval during ultrasound therapy using a 12-MHz probe
dedicated for small structures.
Temperature measurement
A data acquisition board (6251 DAQ, National Instru-
ments, TX, USA) was used to measure the temperature
in the artery. An analogue input of the board is used to
capture the temperature. An Omega (M2813-1205,
OMEGA Engineering, Inc. Stamford, CT, USA) voltage-to-
temperature converter was used to measure temperature
using a software written in MatLab (The Mathworks Inc.,
Natick, MA, USA). A thermocouple (Omega Engineering)
was placed in the carotid artery to measure temperature
elevation at the surface of the transducer since at that
point maximum temperature is achieved. The size of the
Table 1 Lumen reduction extracted from histology as
percentage with respect to the original size for the three
arteries under examination (aorta, abdominal, and
carotid) as a function of month elapsed after the
initiation of the diet
Aorta N Average reduction of area (%) std
Month 0 3 0 0
Month 1 3 15 4
Month 2 3 30 4.5
Month 3 3 48 9
Month 4 3 52 12
Abdominal N Average reduction of area (%) std
Month 0 3 0 0
Month 1 3 12 3
Month 2 3 27 5.3
Month 3 3 43 8.3
Month 4 3 44 12
Carotid N Average reduction of area (%) std
Month 0 3 0 0
Month 1 3 11 4
Month 2 3 22 2.5
Month 3 3 27 6.3
Month 4 3 32 8.8
The standard deviation of the average reduction in the lumen size is
also provided.
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action with the beam of ultrasound is minimized.
Results
Figure 3 shows photos of the rabbit aorta with HE staining
indicating the growth of the plaque within the artery: A)
0 months, B) 1 month, C) 2 months, and D) 3 months. In
order to acquire histology for a specific rabbit, the animal
was sacrificed. Therefore, the photos of Figure 3 are taken
from different rabbits. Care was taken that all three rabbits
in this study were of the same age and weight (as much as
possible).
Table 1 shows the lumen area reduction obtained using
histology, expressed as percentage with respect to the ori-
ginal size for the three arteries under examination (aorta,
abdominal, and carotid), as a function of months elapsed
after the initiation of the diet. The standard deviation of
the average reduction in the lumen size is also provided.
The reduction of lumen area with cholesterol diet at any
month was compared with the lumen area without the
diet. It was demonstrated that there is a significant reduc-
tion of the lumen area (p < 0.02, paired t-test, n = 3) with
high cholesterol diet. A value of p > 0.05 was only ob-
served when comparing months 4 and 3, indicating that
after month 3, the lumen area is not reduced further.
Figure 4 shows typical plaques in the carotid artery as
imaged with ultrasound at 12 MHz. In three of the
cases, the reduction occurs in one side of the carotid ar-
tery. In one case the plaque appears on both sides of the
carotid artery (Figure 4C).
Figure 5 shows the steady state temperature measured
with a thermocouple in the carotid with respect to duty
factor (DF) with intensity of 30 W/cm2 (SAPA), and
PRF = 100 Hz. Note that with DF greater than 10%, the
steady state temperature increases above 1°C and there-
fore some thermal effects are observed.B
C D
A
Figure 3 Photos of the rabbit aorta with HE staining indicating
the growth of the plaque within the artery. 0 months (A),
1 month (B), 2 months (C), and 3 months (D).Figure 6A shows the ultrasonic image of plaque in the
carotid of the rabbit with a plaque after 3 months of diet.
Figure 6B shows the ultrasonic image after the application
of ultrasound with I = 30 W/cm2 (SAPA), PRF = 100 Hz,
and DF = 10%. The plaque was removed after five sessions
of 5-min injection of microbubbles. Note that almost all
the plaque is removed. Figure 6C shows the photo of theA B
C D
Figure 4 Typical plaques in the rabbit carotid as imaged with
ultrasound at 12 MHz. In three of the cases, the reduction occurs
in one side of the rabbit carotid artery (A, B, D). In one case, the
plaque appears on both sides of the artery (C). Plaques are indicated
with arrows.
Figure 5 Steady state temperature measured in the carotid
with respect to DF with intensity of 30 W/cm2 (SAPA), and
PRF = 100 Hz. Note that with DF above 10%, the temperature


























Figure 6 Therapy results. Ultrasonic image of the plaque in the carotid o
during plaque destruction, and frequency spectrum during the destruction
a plaque after 3 months of diet (A). Ultrasonic image after the application
The plaque was removed after five sessions of 5-min injection of microbub
amount of residual plaque (C). Temperature measured during the destruct
(D). Frequency spectrum at one instance during the destruction of plaque
cavitation (E).
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residual plaque. Figure 6D shows the temperature measured
during the destruction of plaque, indicating temperature
increase of approximately 1°C. Figure 6E shows the fre-
quency spectrum at one instance, during the destruction
of plaque, indicating only subharmonic emissions which
are indicative of stable cavitation.
The effect of the intensity on the removal of plaque was
investigated. The carotid of three rabbits was exposed to
different spatial average, pulse average (SAPA) intensity
varying from 10 to 30 W/cm2, with the D.F. and PRF at
10% and 100 Hz, respectively. Figure 7 shows the size of
the plaque removed, as measured from the ultrasound im-

































f the rabbit, photo of the HE staining of the carotid artery, temperature
of plaque. Ultrasonic image of plaque in the carotid of the rabbit with
of ultrasound with I = 30 W/cm2 (SAPA), PRF = 100 Hz, and DF = 10%.
bles (B). Photo of the HE staining of the carotid artery showing small
ion of plaque, indicating temperature increase of approximately 1°C

















Figure 7 Effect of intensity. Size of the plaque removed as
measured from the ultrasound images versus intensity (SAPA),
D.F. = 10%, and PRF = 100 Hz.
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lumen size with the application of ultrasonic intensity at
different levels was compared to the size of the untreated
lumen. It was demonstrated that there is a significant re-
duction of the lumen size (p < 0.05, paired t-test, n = 3)
with ultrasonic intensity.
Conclusions
This paper includes a feasibility study that investigates the
effectiveness of pulsed ultrasound in removing athero-
sclerotic plaque, created in rabbit with the final intention
to remove atherosclerotic plaque from vessels. This feasi-
bility study includes the effect of intensity and DF.
The experiments were conducted in the rabbit carotid
with protocols leading to temperatures less than 1°C (safe
temperature). It was demonstrated in a set of experiments
that if the DF is increased, then the safe temperature is
exceeded. Another parameter that increases the temperature
is the intensity. In these experiments the intensity used was
carefully chosen, and, therefore no temperature elevation
above 1°C was produced. The removed plaque, as expected,
increases with the intensity.
Very promising results were obtained in carrying out ex-
periments in the carotid of rabbits. With this transducer
and protocol we were able to remove atherosclerotic plaque
up to a depth of 2 mm in 25 min. This type of technology
looks promising for the removal of atherosclerotic plaque
in humans, provided that the dissolved material from the
plaque is collected. The collected material must not flow
through the blood stream to other arteries, thus causing
blockage of arteries. Care should be taken to collect all the
removed particles. For example, in studies involving ather-
ectomy [44,45], a suction mechanism was used to collect
the removed particles. Such suction technology can also be
incorporated with this ultrasound technology to remove
the residual particles.
Also, it is possible that if the particle size is too small,
then there is no need to collect the residual particles
and, therefore, the deployment of ultrasound technologywould be more feasible. Yet, clinical studies need to be
done in order to reveal how small this residual particle
must be. This specific device, with this size, can be used
probably in peripheral arteries or in the carotid. Special
design of the device needs to be done so as not to block
the artery. For the application in the heart arteries, the
device must be scaled down to possibly 1 mm.
Previously [40], therapeutic ultrasound was utilized
using its thermal capabilities to ablate plaque in swine.
With thermal ultrasound, plaques are heated and even-
tually destroyed. Due to the close proximity of the
plaque to the artery, crucial thermal damaged tissue
could be produced in the artery. With our method, pulse
ultrasound is used in combination with microbubbles,
and therefore plaque is detached leaving potentially no
severe damage to the artery.
We clearly see the destruction of plaque using ultra-
sonic imaging, but what content of the plaque (lipid, cal-
cium, or microphage) is destroyed first cannot be
assessed accurately with ultrasound imaging.
The combination of pulsed ultrasound and microbub-
bles has been shown to be effective for removing clot [46]
which is a much softer tissue than plaque. The use of
ultrasound alone was ineffective to remove clot [46] in a
rabbit carotid model. Microbubbles are known to cause
stable cavitation and therefore assist the removal of clots.
We speculated that the same effect (stable cavitation)
could accelerate plaque removal. Further experiments
need to be conducted to show that pulsed ultrasound
alone will not be efficient in removing plaque as compared
to pulsed ultrasound in synergy with microbubbles.
This technology can be used in the future for clinical
trials primarily to treat plaques in the carotid. Unstable
plaques in the carotid are a major source of plaques,
which can reach the brain and cause stroke. The device
can be attached to a catheter of appropriate size and the
catheter can be guided intravenously to the carotid for
ultrasonic treatment. Care will be taken to avoid the es-
cape of debris reaching the brain, thus causing stroke.
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